(Q44067892)

29 November 2017

Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer (English)

1 reference

29 November 2017

1 reference

1 reference

1 reference

S Fogli

1

1 reference

29 November 2017

R Danesi

2

1 reference

29 November 2017

A Gennari

3

1 reference

29 November 2017

S Donati

4

1 reference

29 November 2017

P F Conte

5

1 reference

29 November 2017

M Del Tacca

6

1 reference

29 November 2017

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

13

1 reference

29 November 2017

6

1 reference

29 November 2017

919-927

1 reference

Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.

29 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

The taxoids. Comparative clinical pharmacology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Pulmonary function after treatment for acute lymphoblastic leukaemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Some suggestions for measuring predictive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF164

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDF164

1 reference

29 November 2017

1 reference